BioEclipse Therapeutics

BioEclipse Therapeutics

Early Stage

Clinical-stage immunotherapy

Clinical-stage immunotherapy

Overview

Raised this Round: Raised: $0

Total Commitments ($USD)

Platform

Netcapital

Start Date

01/19/2022

Close Date

04/19/2022

Min. Goal
$10,001
Max. Goal
$1,069,998
Min. Investment

$99

Security Type

Equity - Common

Series

Seed

SEC Filing Type

RegCF    Open SEC Filing

Price Per Share

$2.55

Pre-Money Valuation

$28,993,373

Year Founded

2006

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Mountain View, California

Business Type

Growth

BioEclipse Therapeutics, with a valuation of $28.99 million, is raising funds on NetCapital. It is an immunotherapy company using its proprietary technology platform to combine the power of an oncolytic virus with the tumor-locating ability of CIK cells. The technology helps BioEclipse Therapeutics in developing the next generation of immuno-oncology therapeutics. BioEclipse Therapeutics is led by an experienced team and has CRX100 clinical trials underway. Pamela Contag founded BioEclipse Therapeutics in May 2006. The current crowdfunding campaign has a minimum target of $10,000 and a maximum target of $1,069,998. The campaign proceeds will be used for compensation, rent, research, and lab supplies.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$0

$0

COGS

$0

$0

Tax

$0

$0

 

 

Net Income

$-4,391,188

$-2,415,736

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$2,331,499

$5,394,836

Accounts Receivable

$0

$0

Total Assets

$2,956,073

$5,839,337

Short-Term Debt

$75,862

$0

Long-Term Debt

$0

$0

Total Liabilities

$75,862

$0

Financials as of: 01/19/2022
Create a free account today to gain access to Kingscrowd analytics.

Raise History

Offering Name Close Date Platform Valuation Total Raised Security Type Status Reg Type
BioEclipse Therapeutics 04/19/2022 Netcapital $28,993,373 $0 Equity - Common Not Funded RegCF

No prior online funding rounds.

Create a free account today to gain access to Kingscrowd analytics.

Funding data not publicly available

Upgrade to gain access

Pay Monthly
Annually (2 months free)

Edge

$12.50 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific Kingscrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings Kingscrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars
Founders: enhance your startup's credibility on Kingscrowd. Create an account to claim this raise page.
Add to portfolio
BioEclipse Therapeutics on NetCapital 2022
Platform: Netcapital
Security Type: Equity - Common
Valuation: $28,993,373
Price per Share: $2.55

Follow company

Follow BioEclipse Therapeutics on NetCapital 2022

Buy BioEclipse Therapeutics's Deal Report

Warning: according to the close date for this deal, BioEclipse Therapeutics may no longer be accepting investments.

BioEclipse Therapeutics Deal Report

Get Kingscrowd's comprehensive report on BioEclipse Therapeutics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether BioEclipse Therapeutics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the BioEclipse Therapeutics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge